556 results about "Cytotoxicity" patented technology

The invention relates to the technical field of biology, and particularly discloses a recombinant collagen III and application thereof in preparation of gel. The recombinant collagen III is designed by optimizing functional area sequences of human I-type and III-type collagen, the amino acid sequence is shown as SEQ ID No.2, and the recombinant collagen III has the characteristics of high stability, good hydrophilicity and low immunogenicity. The preparation method comprises the steps of expression vector construction, escherichia coli induced expression, affinity chromatography purification and renaturation. The recombinant collagen III can be prepared into a gel dressing and comprises sodium alginate, methylparaben and other components. Experiments show that the gel can effectively promote cell proliferation and has no cytotoxicity; in a mouse skin injury model, the collagen can relieve inflammation, accelerate wound healing and inhibit scar formation, and the effect of the collagen is superior to that of natural human III-type collagen. The invention provides a safe and efficient novel material for wound repair, and is suitable for medical dressings and tissue engineering.

The invention provides an ervatamia divaricata extract as well as a preparation method and application of the ervatamia divaricata extract in resisting brain metastatic tumor. Pharmacological activity shows that the extract of ervatamia divaricata disclosed by the invention has remarkable cytotoxicity inhibition activity, and the inhibition effect of the extract is time-dependent and dose-dependent. The extract can inhibit the growth of breast cancer 4T1 brain metastases, and has no obvious adverse reaction on mice.

The invention belongs to the technical field of polypeptides and biological medicines, and particularly relates to a WK7 series antibacterial peptide and application thereof in the aspects of resisting bacteria and preventing and treating diabetic foot, pneumonia and septicemia. According to the invention, a linear peptide WK7-line with an amino acid sequence of WKRWKRW is used as a minimum active unit, and modification is carried out to form a plurality of linear modified peptides; meanwhile, a cyclic peptide WK7-cyl is formed on the basis of the linear peptide WK7-line through cyclization, and the cyclic peptide WK7-cyl is further modified to form an annular modified peptide. The linear peptide WK7-line, the linear modified peptide, the cyclic peptide WK7-cyl and the cyclic modified peptide jointly form the WK7-series antibacterial peptide, and the WK7-series antibacterial peptide is artificially synthesized polypeptide, is small in molecular weight, easy to synthesize, free of cytotoxicity, almost free of hemolysis risk, high in sterilization speed and broad-spectrum antibacterial property and can be used for preparing the antibacterial peptide. The traditional Chinese medicine composition has a certain effect on prevention and treatment of diabetic foot ulcer, pneumonia and septicemia.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an LL-37 derived antibacterial peptide and application thereof. According to the invention, 17-29aa of the LL-37 antibacterial peptide is used as a core fragment and is connected with an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 through an amido bond, the antibacterial activity of the obtained antibacterial peptide is obviously higher than that of the LL-37 antibacterial peptide, and the antibacterial peptide shows an obvious bactericidal effect on clinical drug-resistant bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, escherichia coli, staphylococcus aureus, klebsiella pneumoniae and the like; meanwhile, the cytotoxicity and hemolytic activity are weak, drug resistance is not prone to being generated, bacteria can be rapidly killed in vivo through multiple mechanisms, no obvious cytotoxicity exists, the bacterium load in tissue is remarkably reduced, and the lifetime of a bacterium-infected mouse is prolonged.

The invention discloses application of domoic acid in preparation of a largemouth bass frog virus inhibitor. The domoic acid disclosed by the invention is relatively low in cytotoxicity, and has an obvious inhibition effect on micropterus salmoides frog virus compared with other microalgal toxins. Further exploration shows that after the micropterus salmoides frog virus is in direct contact with the domoic acid for 12 hours, the micropterus salmoides frog virus is irregular in shape and is completely bright white, so that the domoic acid has a direct destructive effect on the micropterus salmoides frog virus. And the domoic acid can inhibit the process of releasing the micropterus salmoides frog virus to the outside of the cells.

The present invention relates to a method for preparing an acellular dermal matrix derived from a human body, in which the acellular dermal matrix is washed for the second time with an alcohol-based degreasing solution, thereby not only having excellent safety against cytotoxicity, but also being able to effectively remove residual fat.

The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide for inhibiting propionibacterium acnes and application of the antibacterial peptide. The antibacterial peptide for inhibiting propionibacterium acnes is derived from marine organism hylophila, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1. The amino acid sequence is novel, has remarkable antibacterial activity on propionibacterium acnes, has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and can be used for preparing the antibacterial peptide for inhibiting propionibacterium acnes. Due to the characteristics, the compound has huge application potential in the aspect of treating acnes caused by propionibacterium acnes or removing acnes.

The invention is applicable to the technical field of biomedical materials, and provides an anti-inflammatory hemostatic composite gel microsphere and a preparation method and application thereof, and the preparation method comprises the following steps: mixing sodium alginate and baicalin, dissolving in deionized water to obtain a mixed solution, spraying the mixed solution into a calcium chloride solution by utilizing electrospinning and electrospraying, and carrying out electrostatic spinning and electrospraying to obtain the anti-inflammatory hemostatic composite gel microsphere. Gel microspheres are formed through ionic crosslinking; washing the gel microspheres with a calcium chloride solution, and soaking the gel microspheres in a chitosan acetic acid solution to obtain chitosan-encapsulated gel microspheres; placing the gel microspheres in a copper sulfate solution, and performing low-temperature calcium-copper ion exchange to obtain baicalin / copper alginate composite gel microspheres; and filtering, washing and freeze-drying the composite gel microspheres. The electrospray technology is combined with ionic crosslinking, the size and morphology of the microspheres are accurately controlled, the antibacterial effect on escherichia coli and staphylococcus aureus is remarkable, the in-vitro blood coagulation time is shortened by 30%, the cytotoxicity is low, and good biocompatibility is achieved.

The invention provides a medical-grade recombinant three-type collagen and application thereof. The recombinant humanized three-type collagen has certain cell proliferation promoting capacity and is free of cytotoxicity. The medical-grade recombinant three-type collagen provided by the invention not only has the capability of promoting cell proliferation, is free of cytotoxicity and high in cell adhesion activity, but also has a three-helix structure characterized by the collagen and is extremely high in stability, the purity can reach about 85% after the collagen is induced for 120H in a 100L fermentation tank, the difficulty of a downstream purification process is greatly reduced, and the production cost is reduced. The effect in the aspect of cell activity is obvious.

The invention discloses an application of Arcyriaflavin A or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating monkey pox virus infection. The invention finds that the Arcyriaflavin A can obviously inhibit the replication of the monkey pox virus in a Vero cell, and the IC50 of the Arcyriaflavin A for inhibiting the Ib branch monkey pox virus and the IC50 of the Arcyriaflavin A for inhibiting the IIb branch monkey pox virus are 0.66 mu M and 0.96 mu M respectively. The invention also verifies that the Arcyriaflavin A has extremely low toxicity to Vero cells, and the toxicity CC50 of the Arcyriaflavin A to the cells is 41.51 mu M when the Arcyriaflavin A is used for inhibiting the proliferation of the monkey pox virus, so that the Arcyriaflavin A can be used for effectively inhibiting the replication of the monkey pox virus within the safe use range of the Arcyriaflavin A. The invention provides a new choice for the prevention and treatment of monkey pox, and has important significance for the prevention and treatment of monkey pox.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention relates to the field of high polymer material modification, and discloses a low-toxicity nylon material modification composition and a preparation method and application thereof, and the composition comprises the following components by weight: 70-90% of bio-based polyamide; 2-10% of surface functionalized nano-chitosan, wherein a beta-cyclodextrin derivative is grafted on the surface of the surface functionalized nano-chitosan to adsorb harmful small molecules; the 3-15% of double-layer wall material natural polyphenol microcapsules are used for slowly releasing natural polyphenols with anti-oxidation and skin soothing effects; and 0.1-0.5% of an interface synergistic locking agent to enhance the stability of the functional components in the matrix. The preparation method comprises the following steps: mixing the components, and carrying out melt blending granulation through a double-screw extruder. The cytotoxicity of the nylon material is remarkably reduced, the nylon material is endowed with active skin-friendly characteristic and lasting functionality, and the nylon material is suitable for preparing long-term skin contact products such as watchbands and the like.

The invention discloses an antibacterial peptide PA targeting multi-drug-resistant gram-negative bacteria and application of the antibacterial peptide PA, and the amino acid sequence of the antibacterial peptide PA is shown as SEQ ID NO.1. The antibacterial peptide PA provided by the invention has a remarkable antibacterial effect of the multi-drug-resistant gram-negative bacteria, is quick in bactericidal effect, does not have hemolysis and cytotoxicity, does not cause renal toxicity after treatment, and can be used for preparing the antibacterial peptide PA for treating the multi-drug-resistant gram-negative bacteria. The biological safety is good, and the compound can be used for treating bacterial infection and can also be applied to other scenes needing sterilization or bacterial growth inhibition.

The invention discloses a reagent for reducing the agglomeration rate of suspended HEK293F cells, a culture method and a culture medium. The reagent comprises the following components: 0.01-0.1% (v / v) of a nonionic surfactant, 0.05-0.2% (v / v) of polysaccharide or a derivative thereof, 1-5mM of L-glutamine or a derivative thereof, 0.001-0.01 mM of FeCl3, 14-16mM of HEPES and 50-100mu M of an RGD peptide inhibitor. According to the anti-caking agent, the nonionic surfactant, the polysaccharide or the polysaccharide derivative, the L-glutamine or the L-glutamine derivative, the FeCl3, the HEPES and the RGD peptide inhibitor are optimally proportioned, so that the HEK293F cell caking rate is remarkably reduced to 30% or below, after the anti-caking agent is added, cells are in a uniform single-cell suspension state, macroscopic cell agglomerates do not exist, and the anti-caking effect is good. The uptake efficiency of cells on nutrient substances is obviously improved. Compared with a commercially available PEG (Polyethylene Glycol)-containing anti-caking agent, the anti-caking agent disclosed by the invention has the advantages that the anti-caking rate is lower than 35% (the anti-caking rate is only 30% vs after being cultured for 48 hours, and the anti-caking rate is 40%) while the cell viability is maintained to be 95% or above, and no cytotoxic accumulation exists after long-term passage (more than or equal to 20 generations).

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

Systems and methods consistent with the present invention generally relate to microorganospheres (MOSs), and methods and apparatuses for forming and using MOSs. More particularly, in some embodiments, systems and methods consistent with the invention relate to the methods and apparatuses for forming and using MOSs generated from hepatocytes. MOSs that are generated from hepatocytes are suitable for testing liver toxicity and drug induced liver injury effects of various agents.

This invention discloses an antimicrobial peptide PA targeting multidrug-resistant Gram-negative bacteria and its application. The amino acid sequence of the antimicrobial peptide PA is shown in SEQ ID NO.1. The antimicrobial peptide PA provided by this invention has a significant antibacterial effect against multidrug-resistant Gram-negative bacteria, and has a rapid bactericidal onset, no hemolysis or cytotoxicity, does not cause nephrotoxicity after treatment, and has good biosafety. It can be used for the treatment of bacterial infections and can also be applied to other scenarios that require bactericidal or antibacterial growth inhibition.

The invention discloses a milk-derived broad-spectrum antibacterial peptide W-2 and application thereof, and relates to the technical field of biology. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO. 4. Symmetrical structure design and amino acid mutation are carried out on the basis of the template peptide to obtain the novel antibacterial peptide, and tests show that the novel antibacterial peptide has broad-spectrum antibacterial activity which is obviously higher than that of the template peptide, and basically has no cytotoxicity. The antibacterial peptide prepared by the invention still keeps good antibacterial activity in physiological salt concentration and protease environment, has certain serum stability, and has higher application value; in addition, the antibacterial peptide has a good inhibition effect on the formation of a bacterial biofilm, and has a synergistic effect with traditional antibiotics.

The invention discloses a (-)-menthol group-containing nicotinamide derivative with antifungal activity as well as a preparation method and application thereof, and relates to the technical field of synthesis of agricultural chemicals. The derivative has a structure as shown in a general formula (I), in the formula, n is an integer from 1 to 5, and R1, R2, R3 and R4 are specific substituent groups. Through a molecular hybridization strategy, the (-)-menthol, the N-fatty acyl piperazine bridge and the nicotinamide fragment are covalently linked, and a compound with a brand new structure is created. A biological activity test shows that the series of compounds have remarkable inhibitory activity on various plant pathogenic fungi, especially sclerotinia sclerotiorum and valsa mali of apple trees, and are low in cytotoxicity. Molecular docking research proves that the action target of the gene is succinate dehydrogenase (SDH). The invention provides a valuable leading structure for developing novel SDHI bactericides.

This invention provides a non-cytotoxic, in vivo compatible proximity labeling method for peroxidases, Hi-APEX, and its applications, belonging to the field of biotechnology. This invention provides a method for labeling interacting proteins, neighboring proteins, and / or neighboring RNA. By introducing TP probes, it completely overcomes the core limitation of peroxidase dependence on H2O2 without sacrificing the original high spatiotemporal resolution. The method provided by this invention exhibits significantly superior technical effects compared to existing technologies in terms of reduced toxicity, enabling in vivo application, precise analysis of redox-sensitive processes, dynamic tracking of protein transport, and simultaneous spatial multi-omics analysis. It provides a powerful tool for life science research and drug development, possessing significant scientific value and broad application prospects.

The invention relates to the technical field of biological pharmacy, and particularly discloses application of antibacterial small molecule peptide in preparation of antibacterial infection drugs. The antibacterial small molecule peptide is VeAMP, and the amino acid sequence of the antibacterial small molecule peptide is MKIVKRILLVL-NH2. The small molecule peptide VeAMP provided by the invention shows remarkable antibacterial activity on pan-drug-resistant acinetobacter baumannii, has the advantages of rapid sterilization, low hemolysis, low cytotoxicity and good in-vivo safety, is not easy to induce bacterial drug resistance after being exposed for a long time at a sub-inhibitory concentration, can effectively reduce tissue bacterial load, remarkably improves the survival rate of infected mice, and has a good application prospect. The invention provides a novel and safe candidate antibacterial agent which is not easy to generate drug resistance for preventing and treating drug-resistant acinetobacter baumannii infection.

The application belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mp-GC21, a precursor thereof and application. The amino acid sequence of the antibacterial peptide Mp-GC21 is shown as SEQ ID NO:1, wherein the C terminal is subjected to amidation modification, and two cysteines are connected through a disulfide bond; and the amino acid sequence of the precursor is shown as SEQ ID NO:3. The antibacterial peptide Mp-GC21 is separated from the flower frog, has broad-spectrum antibacterial activity, and has good bacteriostatic and bactericidal effects on standard strains and clinically derived drug-resistant strains of Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and can target to destroy the cell membrane of bacteria, remove the biofilm and inhibit the formation of the biofilm. Moreover, the antibacterial peptide Mp-GC21 has good stability, does not have hemolytic activity, cytotoxicity and in-vivo toxicity, and is not easy to induce drug resistance of strains.

The present application provides gastrodia elata (Blume) alkaloids PFT201A, PFT201B and PFT203 and a preparation method thereof, and application thereof in the fields of cosmetics and medicine. Gastrodia elata Gastrodia elata (Blume) alkaloids PFT201A, PFT201B and PFT203 significantly promote the secretion of collagen type II in human dermal fibroblasts-adult (HDFa) at an extremely low concentration (0.1 μ M), and have no cytotoxicity at the concentration. These compounds can be used for preparing anti-aging drugs or skin care products.

The purpose of this invention is to provide a polypeptide with anti-tuberculosis activity, its preparation method, and its application, belonging to the field of biotechnology. The preparation method of the polypeptide of this invention includes the following steps: (1) preparing a linear polypeptide, the sequence of which is shown in SEQ ID NO:1; (2) subjecting the thiol groups of two cysteine ​​residues in the linear polypeptide to a dehydration condensation reaction with 1,3-dihydroxymethylurea to obtain the polypeptide. The polypeptide of this invention has low cytotoxicity and good anti-tuberculosis effect.

The invention belongs to the technical field of machine learning, and provides a multi-model integrated prediction method and system for human breast cancer cytotoxicity caused by ionic liquid, and the main scheme is as follows: collecting experimental data and preprocessing the experimental data; splicing the quantifiable features to form an original feature matrix; performing feature dimension reduction processing on the original features to form an input feature matrix; taking the input feature matrix as input data, training a random forest, XGBoost and MLP basic machine learning model and carrying out model parameter adjustment, carrying out model integration on the trained basic machine learning model based on a weighted average fusion strategy, and selecting an optimal integrated model; evaluating the trained basic machine learning model, and applying the optimal integrated model to prediction of the human breast cancer cell toxicity of the ionic liquid of a new sample; and carrying out model deployment on the trained basic machine learning model and the selected optimal integrated model.

The application discloses a use of phenazine-1-carboxylic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for inhibiting African swine fever virus. The application uses a double reporter virus rASFV-Gluc / EGFP co-expressing green fluorescent protein and Gaussia luciferase to screen 246 natural small molecule compounds, and finds that phenazine-1-carboxylic acid has a significant inhibiting effect on replication of the ASFV; further evaluation of the inhibiting effect finds that the half maximal cytotoxicity concentration of PCA on target cells of primary porcine alveolar macrophages is 470.5 muM, and the half maximal inhibitory concentration of PCA on the ASFV in PAMs is 1.59 muM. According to a dose-dependent inhibiting experiment result, when the concentration of PCA is 25 muM, the inhibiting effect on the ASFV can reach more than 100 times. The application has application prospects in preparation of medicines or preparations against the ASFV.

The application discloses a silver / schiff base antibacterial material, a preparation method and application, and relates to the field of antibacterial materials.The silver / schiff base antibacterial material, the preparation method and the application are characterized in that, based on the large electron cloud density of the carbon-nitrogen double bond of the schiff base, silver ions in a silver nitrate solution are uniformly adsorbed on a schiff base base through the electrostatic adsorption principle; under the reduction of a reducing agent, the silver ions are reduced to nanosilver ions, and a silver / schiff base antibacterial material is obtained, in which nanosilver ions in the form of nanospheres are uniformly dispersed on the schiff base in the form of a thin sheet layer, thereby greatly improving the dispersibility of the nanosilver ions.The preparation method is simple, low in cost, and capable of batch production, and has no cytotoxicity, and has high antibacterial effects on streptococcus, pseudomonas aeruginosa and staphylococcus aureus, and has a good application prospect.

This invention discloses a NK cell culture kit, its culture method, and its application. The kit includes an amplification medium, a high-efficiency induction medium, an NK-A coating solution, an NK-B mixture, and an NK-C mixture. The amplification medium contains basal medium, NAD+, human serum albumin, transferrin, β-glucan, glutathione, β-mercaptoethanol, and linoleic acid. The high-efficiency induction medium, in addition to the amplification medium components, contains soybean peptides, nicotinamide, inulin, and N-acetyl-L-cysteine. The NK-A coating solution contains heparin sodium, monoclonal antibodies, and antibodies. The NK-B mixture contains Inbakicept, IL-2, and IL-15. The NK-C mixture contains linolenic acid, IL-2, and IL-18. The Inbakicept factor in the kit can activate NK cells and enhance their cytotoxicity; linolenic acid can inhibit T cell proliferation, increase NK cell purity, and enhance cell efficacy.

The present invention relates to a composition for wound treatment or skin regeneration, comprising an extract from one or more selected from the group consisting of Trichosanthes kirilowii (T. kirilowii), Pueraria lobata (P. lobata), Liriope platyphylla (L. platyphylla), Poria cocos (P. cocos), Prunus mume (P. mume), Astragalus membranaceus (A. membranaceus), Panax ginseng (P. ginseng), and Glycyrrhiza uralensis (G. uralensis). The composition has low cytotoxicity and exhibits wound-healing effects, particularly therapeutic effects on extensive skin ulcers such as diabetic skin ulcers.